Comparison of current EMA, FDA and ANVISA approaches to peptide-related impurity qualification, comparability and immunogenicity.
The three regulatory systems converge on the need for product-specific scientific justification but differ in how thresholds and comparability are operationalized.
EMA
The current EMA synthetic-peptide guideline is adopted and effective from June 2026, with peptide-specific expectations for manufacturing, characterization, specifications and related impurities.
FDA
The FDA increasingly uses product-specific guidances for generic peptide products; 17 revised draft PSGs were published on 28 July 2026.
ANVISA
Guia 83/2025 provides the current Brazilian framework for impurity qualification and recognizes the need for peptide-specific justification.
Common principle
Comparability and demonstration that differences do not introduce additional safety or immunogenicity concern are central themes.
Frequently asked questions
Are the three frameworks identical?
No.
Does FDA use one universal threshold scheme for all peptides?
No. Product-specific guidances are important.
Is the EMA peptide guideline now final?
Yes, the current version is adopted.
Does ANVISA address peptide-related impurities?
Yes, Guia 83/2025 includes a specific rationale for these impurities.
